Last updated: February 24, 2026
What is NDC 00143-9300?
NDC 00143-9300 corresponds to Aduhelm (aducanumab) injection, approved by the FDA in June 2021 for the treatment of Alzheimer's disease. It is an amyloid beta-directed antibody designed to reduce amyloid plaques in the brain. The drug was developed by Biogen and licensed to Eisai.
Market Overview
Therapeutic Context
Alzheimer's disease affects approximately 6.2 million Americans, with total US healthcare costs exceeding $355 billion annually. The approval of Aduhelm represents a potential shift in treatment paradigms, targeting disease pathology directly through amyloid clearance.
Market Size and Adoption
In 2022, the Alzheimer's drug market was valued at approximately $2.8 billion, with projections reaching $4.5 billion by 2027. Aduhelm's market penetration remains limited due to several factors including clinical controversy, reimbursement hurdles, and safety concerns.
Regulatory and Reimbursement Factors
- FDA approval (June 2021): Controversial approval process due to mixed clinical trial results.
- CMS reimbursement guidelines: Initially restricted to clinical trial settings; expanded to broader Medicare coverage in July 2022, subject to utilization management protocols.
- Pricing: Launched at $56,000 per year per patient, with a list price set accordingly.
Competitors and Pipeline
- No direct rivals approved for amyloid reduction; however, emerging therapies in phase 3 include Eli Lilly's donanemab and Roche's gantenerumab, targeting similar mechanisms.
- Other drug candidates focus on tau pathology, with different therapeutic approaches.
Price Projection Factors
Historical Pricing Dynamics
- Launched at $56,000/year.
- Negotiation pressures and reimbursement reforms may influence future pricing.
- Cost-effectiveness assessments vary; the FDA and payers are evaluating clinical benefit against high costs.
Reimbursement and Market Penetration
- CMS indicators suggest incremental adoption in Medicare populations.
- Transitioning to wider outpatient use may negotiate lower payer prices.
Cost-Effectiveness Analysis
Based on current clinical data, the incremental cost-effectiveness ratio (ICER) for Aduhelm exceeds traditional thresholds ($50,000–$150,000/QALY), pressuring manufacturers to revise pricing or improve clinical outcomes.
Price Trends (2023-2027)
| Year |
Estimated Price |
Notes |
| 2023 |
$56,000 |
Initial launch price |
| 2024 |
$50,000–$55,000 |
Potential discounts due to reimbursement negotiations; insurance coverage policies |
| 2025 |
$45,000–$50,000 |
Industry pressure for cost reduction; competitive pressures from pipeline drugs |
| 2026 |
$40,000–$45,000 |
Continued market stabilization; expanded payer negotiations |
| 2027 |
$35,000–$40,000 |
Turnover toward value-based pricing models |
Key Influences on Future Pricing
- Clinical efficacy evidence from ongoing post-approval studies.
- Outcomes of negotiations with CMS and private payers.
- Competitive landscape changes with pipeline drugs gaining approval.
- Policy shifts favoring value-based pricing models.
Strategic Considerations for Stakeholders
- Biogen/Eisai: Potential to lower list prices to improve reimbursement rates and uptake.
- Providers: Must navigate evolving reimbursement policies and evaluate clinical benefit relative to cost.
- Payers: Push for outcomes-based agreements and utilization management to control costs.
- Investors: Monitor pipeline development and regulatory decisions for pricing and market share shifts.
Summary
Aduhelm's market and pricing trajectory remains uncertain due to clinical, regulatory, and reimbursement factors. Initial high pricing may decline as wider adoption occurs, contingent on demonstrated clinical benefit and negotiation outcomes with payers.
Key Takeaways
- NDC 00143-9300 (Aduhelm) launched at $56,000/year with limited initial reimbursement.
- Clinical efficacy controversy impacts market penetration and future pricing.
- Reimbursement policies and pipeline competition influence downward price pressure.
- Long-term prices may decline to $35,000–$40,000/year, contingent on clinical value and payer negotiations.
- Market adoption remains cautious; widespread utilization depends on evolving clinical evidence and policy adjustments.
FAQs
-
How does Aduhelm's clinical efficacy influence its market price?
Clinical efficacy, especially shown in post-approval studies, directly impacts payer acceptance and the potential for price discounts.
-
What factors are most likely to cause a price decrease for this drug?
Reimbursement restrictions, negative clinical data, increased competition, and policy shifts toward value-based pricing.
-
How does the approval process affect future market access?
A controversial approval limits initial adoption; subsequent reimbursement decisions and clinical outcomes will determine long-term access.
-
Is the pipeline threatening Aduhelm’s market share?
Yes, drugs like Eli Lilly’s donanemab are in late-stage trials and could offer efficacy benefits, providing competitive pressure.
-
What is the outlook for Aduhelm’s pricing in the next five years?
A downward trend is expected, with prices possibly reaching $35,000–$40,000/year by 2027, influenced by clinical, regulatory, and market dynamics.
References
[1] Food and Drug Administration. (2021). FDA Approves Aduhelm for Alzheimer's Disease.
[2] Centers for Medicare & Medicaid Services. (2022). Coverage for Aduhelm.
[3] Market Data for Alzheimer's Treatments (2022). IQVIA.
[4] Biogen. (2021). Aduhelm (aducanumab) Prescribing Information.
[5] Benchmark Price Trends for Alzheimer's Therapies (2023). EvaluatePharma.
